Vitreous concentration of topically applied brimonidine tartrate 0.2%

Kent, A. R., Nussdorf, J. D., David, R., Tyson, F., Small, D. and Fellows, D. (2001). Vitreous concentration of topically applied brimonidine tartrate 0.2%. In: Annual Meeting of the American Glaucoma Society, San Antonio TX, United States, (784-787). March 2000. doi:10.1016/S0161-6420(00)00654-0


Author Kent, A. R.
Nussdorf, J. D.
David, R.
Tyson, F.
Small, D.
Fellows, D.
Title of paper Vitreous concentration of topically applied brimonidine tartrate 0.2%
Conference name Annual Meeting of the American Glaucoma Society
Conference location San Antonio TX, United States
Conference dates March 2000
Journal name Ophthalmology   Check publisher's open access policy
Place of Publication Philadelphia, PA, United States
Publisher Elsevier
Publication Year 2001
Sub-type Fully published paper
DOI 10.1016/S0161-6420(00)00654-0
ISSN 0161-6420
1549-4713
Volume 108
Issue 4
Start page 784
End page 787
Total pages 3
Language eng
Formatted Abstract/Summary
Objective: To determine the vitreous concentration of brimonidine after topical administration of Alphagan.

Design: Prospective observational case series. Participants: Eighteen patients scheduled for elective pars plana vitrectomy.

Methods: Brimonidine tartrate, 0.2%, was topically administered twice or three times daily for 4 to 14 days preoperatively in 13 patients. Four patients served as controls, without application of brimonidine. A dry, undiluted vitrectomy specimen obtained intraoperatively was collected, frozen, and sent to an independent bioanalytical facility for quantitative determination of vitreous concentration of brimonidine using gas chromatography/mass spectrometry.

Main Outcome Measures: The concentration of brimonidine in human vitreous.

Results
: All patients treated with brimonidine measured above the lower limit of quantitation with a mean vitreous concentration of 185 ± 500 nM. All patients not treated with brimonidine measured at or below the lower limit of quantitation of 0.05 nM. There was a trend toward higher concentration in patients who were either aphakic or pseudophakic compared with those that were phakic.

Conclusions: Topically applied brimonidine results in vitreous levels at or above 2 nM, the concentration shown to activate α 2-receptors.
Keyword GLAUCOMA
AGONISTS
DAMAGE
Q-Index Code E1
Q-Index Status Provisional Code
Institutional Status Non-UQ

Document type: Conference Paper
Collection: School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 42 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 51 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Mon, 14 Mar 2011, 09:56:24 EST